Balloon Angioplasty

WASHINGTON — A new study supports the safety and effectiveness of the Chocolate Touch drug-coated balloon for the treatment of symptomatic peripheral arterial disease with lesions in superficial femoral and popliteal arteries.

In a real-world registry of patients with peripheral artery disease, 5-year outcomes of a drug-coated balloon were positive regardless of sex and diabetes status, researchers reported at the International Symposium on Endovascular Therapy.

Contemporary data suggest paclitaxel-coated devices do not elevate mortality risk in patients with peripheral artery disease, and they should be used more routinely, according to a speaker.

According to a prespecified analysis of the BASKET-SMALL 2 trial, reperfusion with a drug-coated balloon in patients with CAD and small vessels may be noninferior to a drug-eluting stent, regardless of the indication for PCI.

In patients with peripheral artery disease and femoropopliteal lesions, a low-dose paclitaxel-coated balloon enhanced patency and reduced risk for reintervention compared with percutaneous transluminal angioplasty, researchers reported.

In patients with complex peripheral artery disease, a drug-coated balloon performed similarly to how it did in the general PAD population, according to new data from the IN.PACT Global registry.

In a head-to-head trial, a low-dose paclitaxel-coated balloon was noninferior to a higher-dose paclitaxel-coated balloon for treatment of patients with peripheral artery disease.

At 5 years, there was no link between a paclitaxel-coated balloon and excess mortality compared with percutaneous transluminal angioplasty in two studies of patients with peripheral artery disease.

A low-dose paclitaxel-coated balloon was similar to a higher-dose paclitaxel-coated balloon in safety and efficacy among patients with femoropopliteal lesions at 2 years, according to new data from the COMPARE trial.

In a pooled analysis of two randomized controlled trials of a low-dose paclitaxel-coated balloon to treat peripheral artery disease, there was no mortality difference between the paclitaxel-coated balloon and an uncoated balloon at 4 years.